Quarterly report [Sections 13 or 15(d)]

BUSINESS COMBINATION (Details Narrative)

v3.25.2
BUSINESS COMBINATION (Details Narrative) - USD ($)
 6 Months Ended
Mar. 04, 2025
Jun. 30, 2025
Jun. 30, 2024
Dec. 31, 2024
Oct. 14, 2024
BUSINESS COMBINATION          
Retention description amounts equal $400,000 of 50% of the Net Sales (as defined in the APA) of Lucemyra and 50% of the Net Distributable Profits (as defined in the APA) of the generic version of Lucemyra        
Common stock shares issued 500,000 104,500 30,000    
Common stock purchase 500,000        
Common stock price per share $ 0.31 $ 0.001   $ 0.001 $ 0.75
Exercise price $ 1.00        
Fair value of stock issued $ 153,500        
Discounted at the risk-free rate   4.04%      
Upfront purchase price $ 400,000 $ 392,441      
Discounted at required metric risk premium   $ 27.78      
Business contributed revenues   $ 311,347      
Earnings   258,504      
Acquisition-related costs   219,359      
Pro forma adjusted amount   219,359      
Royalty payments   $ 192,365